Search research articles
Contact Us
Filters
Showing results (791-800 of 921) with videos related to
Page
of 93
Sort By:
JACC. Heart Failure
|
March 16, 2020
Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper
Nasrien E Ibrahim, John C Burnett, Javed Butler, et al.
The Cleft Palate-Craniofacial Journal : Official Publication of the American Cleft Palate-Craniofacial Association
|
July 28, 2022
Intellectual Functioning of Children With Isolated PRS, PRS-Plus, and Syndromic PRS
Stephanie Malarbi, Anita K Chisholm, Julia K Gunn-Charlton, et al.
Regulatory Peptides
|
April 2, 2003
Ventricular adrenomedullin is associated with myocyte hypertrophy in human transplanted heart
Toshihiro Tsuruda, Michihisa Jougasaki, Guido Boerrigter, et al.
Journal of the American Heart Association
|
July 27, 2019
Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease
Yogesh N V Reddy, Seethalakshmi R Iyer, Christopher G Scott, et al.
JAMA
|
March 27, 2007
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials
Mihai Gheorghiade, Marvin A Konstam, John C Burnett, et al.
Circulation
|
April 1, 1994
Endothelin in human congestive heart failure
C M Wei, A Lerman, R J Rodeheffer, et al.
Stem Cell Research
|
October 30, 2016
Induced pluripotent stem cells (iPSC) created from skin fibroblasts of patients with Prader-Willi syndrome (PWS) retain the molecular signature of PWS
Lisa C Burnett, Charles A LeDuc, Carlos R Sulsona, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology
|
December 1, 2017
CRRL269: a novel designer and renal-enhancing pGC-A peptide activator
Yang Chen, Gail J Harty, Brenda K Huntley, et al.
American Heart Journal
|
June 7, 2011
Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials
Peter S Pang, Mihai Gheorghiade, Jamil Dihu, et al.
Circulation. Cardiovascular Genetics
|
March 16, 2013
Natriuretic peptide receptor-3 gene (NPR3): nonsynonymous polymorphism results in significant reduction in protein expression because of accelerated degradation
Naveen L Pereira, Dong Lin, Linda Pelleymounter, et al.
Page
of 93
Search research articles
Search
Showing results (791-800 of 921) with videos related to
Sort By:
Page
of 93
JACC. Heart Failure
|
March 16, 2020
Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper
Nasrien E Ibrahim, John C Burnett, Javed Butler, et al.
The Cleft Palate-Craniofacial Journal : Official Publication of the American Cleft Palate-Craniofacial Association
|
July 28, 2022
Intellectual Functioning of Children With Isolated PRS, PRS-Plus, and Syndromic PRS
Stephanie Malarbi, Anita K Chisholm, Julia K Gunn-Charlton, et al.
Regulatory Peptides
|
April 2, 2003
Ventricular adrenomedullin is associated with myocyte hypertrophy in human transplanted heart
Toshihiro Tsuruda, Michihisa Jougasaki, Guido Boerrigter, et al.
Journal of the American Heart Association
|
July 27, 2019
Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease
Yogesh N V Reddy, Seethalakshmi R Iyer, Christopher G Scott, et al.
JAMA
|
March 27, 2007
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials
Mihai Gheorghiade, Marvin A Konstam, John C Burnett, et al.
Circulation
|
April 1, 1994
Endothelin in human congestive heart failure
C M Wei, A Lerman, R J Rodeheffer, et al.
Stem Cell Research
|
October 30, 2016
Induced pluripotent stem cells (iPSC) created from skin fibroblasts of patients with Prader-Willi syndrome (PWS) retain the molecular signature of PWS
Lisa C Burnett, Charles A LeDuc, Carlos R Sulsona, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology
|
December 1, 2017
CRRL269: a novel designer and renal-enhancing pGC-A peptide activator
Yang Chen, Gail J Harty, Brenda K Huntley, et al.
American Heart Journal
|
June 7, 2011
Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials
Peter S Pang, Mihai Gheorghiade, Jamil Dihu, et al.
Circulation. Cardiovascular Genetics
|
March 16, 2013
Natriuretic peptide receptor-3 gene (NPR3): nonsynonymous polymorphism results in significant reduction in protein expression because of accelerated degradation
Naveen L Pereira, Dong Lin, Linda Pelleymounter, et al.
Page
of 93